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Patient preferences in benefit-risk assessment 
 Patient preferences matter 
 They experience the benefits and risks 
 Preferences can differ between regulators and patients  
 Example: Natalizumab case 
 Growing interest (FDA, EMA) 
 Little known about integrating preferences into assessments 
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The MCDA model 
18 Oct 2012 H Broekhuizen SMDM presentation 3 
Clinical trial 
data 
Approximation 
Patient 
preferences 
Uncertainty Uncertainty 
Preference 
studies 
Clinical trials 
Simulation 
Risk-benefit plane Sensitivity graphs 
Case study: antidepressants 
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Patient 
preferences 
Uncertainty 
Preference 
studies 
 Preferences: Analytical 
Hierarchy Process study by 
Danner et al. (2011) 
 Respondents: 12 MDD 
patients 
 Benefit criteria: response and 
remission 
 Risk criterion: adverse events 
(low and high severity) 
 Benefit and risk outcomes 
assumed to be independent 
 Approximated by a bootstrap 
resampling method 
How is preference information approximated? 
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 Approximated by a bootstrap 
resampling method 
Case study: antidepressants 
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Clinical trial 
data 
Uncertainty 
Clinical trials 
 Performance: Systematic 
review by German Institute for 
Quality and Efficiency in 
Health Care (IQWIG) 
 Drugs: Duloxetine, 
Venlafaxine and Bupropion 
 Odds ratio compared to 
placebo 
How is clinical data approximated? 
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 Approximated by a normal 
distribution in the log domain 
Bupropion remission performance
OR compared to placebo
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Remission OR (Bupr pion compared to placebo) 
 For a particular drug i in simulation run t, 
 
𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠𝑖,𝑡 =
𝑊𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑡
𝑊𝑟𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑡
⋅
𝑂𝑅𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑖,𝑡
𝑂𝑅𝑟𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛𝑡,𝑖
 
 
𝑅𝑖𝑠𝑘𝑠𝑖,𝑡 = 𝑊𝐴𝐸𝑡 ⋅ 𝑂𝑅𝐴𝐸𝑖,𝑡 
 
𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑅𝑖𝑠𝑘𝑅𝑎𝑡𝑖𝑜𝑖,𝑡 = 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠𝑖,𝑡 𝑅𝑖𝑠𝑘𝑠𝑖,𝑡  
 
 Benefits and risks plotted in risk-benefit plane 
 
Integration of patient preferences and clinical data 
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Risk-benefit plane 
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Weighted benefits (OR) 
 μ is decision threshold, μ=1 requires 
drugs to have >1 weighted benefit for 
each weighted risk to be acceptable, 
i.e: 
 Benefit-risk-ratio>μ  benefits 
outweigh risks 
 Percentage points under line 
approximates P(acceptable) 
Comparing benefits and risks in the risk-benefit plane 
Risk-benefit plane 
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Sensitivity 
 What is the impact of uncertainty surrounding model parameters 
 Important distinction (Felli 1998) 
 Value sensitivity (change in expected value) 
 Decision sensitivity (change in decision, i.e. other drug chosen) 
 Ranking sensitivity (change in rank order of drugs) 
 Why would we want to know? 
 Robustness 
 Heterogeneity 
 Insight for further research 
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Decision sensitivity 
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Ranking sensitivity 
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Rank reversal 
P(rank=1) 
P(rank=2) 
P(rank=3) 
Venlafaxine response performance (OR compared to placebo) 
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Discussion 
 Integration preferences and performance 
 Impact uncertainty can be assessed 
 Visual representations can help regulators and enrich the 
discussion during the benefit-risk assessment proces.  
 
 Assumptions in antidepressants case 
 Simplified structure 
 Independence 
 What probability is convincing? 
 Other methods needed to check external validity 
 Model cannot make decisions, only assist regulators 
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Thank you 
 
 
 
 
 
 
 
 
 
 Email: h.broekhuizen@utwente.nl 
 Web:   www.utwente.nl/mb/htsr/Staff/broekhuizen.doc/ 
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